Faycal El Guendouz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Faycal El Guendouz has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Sara Derrou
8 shared publicationsSomaya Safi
6 shared publicationsAmal Moumen
4 shared publications- Abdelaziz Hommadi
Department of Radiology, third Military Hospital, El Aiun, Morocco
3 shared publications Hassan Ouleghzal
Moulay Ismail Military Hospital of Meknes, Sidi Mohamed Ben Abdellah University, Fes, Morocco
3 shared publicationsYousra Benabdelfdil
3 shared publications
Latest Publications
- 1 February 2026
- Published by JLE in Cahiers Santé Médecine thérapeutique
- Vol. 35 (1) , 24-30
Liver disorders associated with synthetic antithyroid drugs
- 1 February 2026
- Published by JLE in Cahiers Santé Médecine thérapeutique
- Vol. 35 (1) , 24-30
Liver disorders associated with synthetic antithyroid drugs
- Open Access
- 14 October 2025
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 52 (71)
Suprasellar arachnoid cyst revealed by central diabetes insipidus
We report the case of a 29-year-old man with severe polyuria and polydipsia (~25 litres per day) affecting the quality of the patient's sleep, persistent fatigue, and chronic headaches. Laboratory evaluation revealed hypernatremia (145 mmol/L), elevated plasma osmolality (298.65 mOsm/kg), which contrasts with low urine osmolality (121 mOsm/kg), confirming diabetes insipidus without deficient secretion of anterior pituitary hormones. The desmopressin administration test confirmed the diagnosis of central diabetes insipidus, showing a total response to desmopressin. Magnetic resonance imaging of the hypothalamic-pituitary region revealed an arachnoid cyst with the absence of the posterior pituitary bright spot (A), while the anterior pituitary gland appeared preserved (B). Treatment was conservative with simple desmopressin replacement therapy without surgery. This case illustrates the rare association between an arachnoid cyst and central diabetes insipidus, probably due to chronic hypothalamic compression rather than traction of the pituitary stalk. Prompt recognition and management are crucial for restoring fluid balance, improving sleep, reducing fatigue, and minimising the psychosocial impact. This report highlights the clinical importance of hypothalamic-pituitary MRI in the management of central diabetes insipidus without resorting to the fluid deprivation test, which is a test poorly tolerated by patients.
- 14 October 2025
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 52 (71)
Open AccessSuprasellar arachnoid cyst revealed by central diabetes insipidus
We report the case of a 29-year-old man with severe polyuria and polydipsia (~25 litres per day) affecting the quality of the patient's sleep, persistent fatigue, and chronic headaches. Laboratory evaluation revealed hypernatremia (145 mmol/L), elevated plasma osmolality (298.65 mOsm/kg), which contrasts with low urine osmolality (121 mOsm/kg), confirming diabetes insipidus without deficient secretion of anterior pituitary hormones. The desmopressin administration test confirmed the diagnosis of central diabetes insipidus, showing a total response to desmopressin. Magnetic resonance imaging of the hypothalamic-pituitary region revealed an arachnoid cyst with the absence of the posterior pituitary bright spot (A), while the anterior pituitary gland appeared preserved (B). Treatment was conservative with simple desmopressin replacement therapy without surgery. This case illustrates the rare association between an arachnoid cyst and central diabetes insipidus, probably due to chronic hypothalamic compression rather than traction of the pituitary stalk. Prompt recognition and management are crucial for restoring fluid balance, improving sleep, reducing fatigue, and minimising the psychosocial impact. This report highlights the clinical importance of hypothalamic-pituitary MRI in the management of central diabetes insipidus without resorting to the fluid deprivation test, which is a test poorly tolerated by patients.
- Open Access
- 18 July 2025
- Published by Wolters Kluwer Health in Chronicle of Diabetes Research and Practice
- Vol. 4 (2) , 80-85
The Impact of Ramadan on Glycemic Control: Effect on Glycemic Variability and Metrics of Glycemic Management Derived from Continuous Glucose Monitoring
Introduction: Fasting during Ramadan alters dietary habits and metabolic balance, potentially affecting glycemic control in people with diabetes. This study aimed to assess the impact of Ramadan on metrices and glycemic variability parameters using continuous glucose monitoring (CGM) in patients with diabetes, irrespective of their diabetes type or fasting status. Methods: This was a prospective and analytical study conducted in the Endocrinology Department of a Military Hospital in Morocco during Ramadan 2024. We included patients with diabetes equipped with CGM who had received specialized Ramadan education. In addition to demographic and anamnesis data, we compared two ambulatory glucose profile reports, one before Ramadan and another immediately after. The parameters compared were: mean glucose index, glucose management indicator, time in range, time above range, time below range, coefficient of variation, standard deviation, mean amplitude of glycemic excursions, mean daily differences, the number and duration of hypoglycemic episodes, CGM composite index, and glycemic risk index. Results: Eighteen patients were included, with a mean age of 43 years and a mean glycated hemoglobin of 6.9%. Eight patients chose to fast. No impact of Ramadan was observed on CGM-derived glycemic management parameters, regardless of the type of diabetes or the patients’ decision to fast. Conclusion: Our study suggests that CGM use combined with specialized Ramadan education may counterbalance the known impact of this month on glycemic control and variability.
- 18 July 2025
- Published by Wolters Kluwer Health in Chronicle of Diabetes Research and Practice
- Vol. 4 (2) , 80-85
Open AccessThe Impact of Ramadan on Glycemic Control: Effect on Glycemic Variability and Metrics of Glycemic Management Derived from Continuous Glucose Monitoring
Introduction: Fasting during Ramadan alters dietary habits and metabolic balance, potentially affecting glycemic control in people with diabetes. This study aimed to assess the impact of Ramadan on metrices and glycemic variability parameters using continuous glucose monitoring (CGM) in patients with diabetes, irrespective of their diabetes type or fasting status. Methods: This was a prospective and analytical study conducted in the Endocrinology Department of a Military Hospital in Morocco during Ramadan 2024. We included patients with diabetes equipped with CGM who had received specialized Ramadan education. In addition to demographic and anamnesis data, we compared two ambulatory glucose profile reports, one before Ramadan and another immediately after. The parameters compared were: mean glucose index, glucose management indicator, time in range, time above range, time below range, coefficient of variation, standard deviation, mean amplitude of glycemic excursions, mean daily differences, the number and duration of hypoglycemic episodes, CGM composite index, and glycemic risk index. Results: Eighteen patients were included, with a mean age of 43 years and a mean glycated hemoglobin of 6.9%. Eight patients chose to fast. No impact of Ramadan was observed on CGM-derived glycemic management parameters, regardless of the type of diabetes or the patients’ decision to fast. Conclusion: Our study suggests that CGM use combined with specialized Ramadan education may counterbalance the known impact of this month on glycemic control and variability.
- Open Access
- 1 January 2025
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 52 (79)
Ultrasonographic image of a rare case of papillary thyroid carcinoma from a thyroglossal cyst
A 28-year-old female patient with no significant medical history presented with a midline cervical mass. The lesion had been present since childhood but remained stable and asymptomatic until recently
- 1 January 2025
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 52 (79)
Open AccessUltrasonographic image of a rare case of papillary thyroid carcinoma from a thyroglossal cyst
A 28-year-old female patient with no significant medical history presented with a midline cervical mass. The lesion had been present since childhood but remained stable and asymptomatic until recently
- Open Access
- 1 January 2025
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 52 (55)
Cranial vault metastasis revealing follicular thyroid carcinoma
We retrospectively report on a 52-year-old man who presented with intercurrent disease and signs of intracranial hypertension in our emergency department. He had a headache, vomiting, and photophobia.
- 1 January 2025
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 52 (55)
Open AccessCranial vault metastasis revealing follicular thyroid carcinoma
We retrospectively report on a 52-year-old man who presented with intercurrent disease and signs of intracranial hypertension in our emergency department. He had a headache, vomiting, and photophobia.
- 1 December 2024
- Published by JLE in Cahiers Santé Médecine thérapeutique
- Vol. 33 (6) , 326-332
Gestational diabetes mellitus: news and controversies
- 1 December 2024
- Published by JLE in Cahiers Santé Médecine thérapeutique
- Vol. 33 (6) , 326-332
Gestational diabetes mellitus: news and controversies
- Open Access
- 31 July 2024
- Published by University of Toronto Libraries - UOTL in University of Toronto Medical Journal
- Vol. 101 (2)
Predicting malignancy of thyroid nodule using EU-TIRADS ultrasound score in an area of iodine deficiency
Background: In iodine-deficient region, thyroid nodules (TN) are more frequent and the proportion of benign nodules is higher compared to areas with sufficient iodine intake. Objective The aim of this study was to assess factors associated to malignant TN specially the Eu-TIRADS ultrasound score in a Moroccan population with high prevalence of iodine deficiency. Methods: In a prospective cross-sectional study, we enrolled outpatients referred for TN with Fine Needle Aspiration Biopsy (FNAB) indication according to EU-TIRADS 2017 classification. Malignancy of TN was defined by histological results indicating a thyroid malignancy on thyroid micro-biopsy or after surgical resection if indicated. Results: 225 TN were enrolled. The median of the patients’ age was 54 (42.5 ; 62) years-old. The prevalence of malignant TN was 8.9%. Malignant TN were significantly smaller than non-malignant ones (p = 0.008) and sub-centimetric TN were more frequent in malignant TN (25% vs 1.5%; p < 0.001). On multivariate analysis, male gender (OR : 9.33 ; 95% CI [2.02 ; 43.01]; p = 0,004) and EU-TIRADS 5 score (OR : 55.6 ; 95% CI [9.34 ; 327.91] ; p < 0.001) were independent factors associated with malignant TN. The EU-TIRADS 4 score was not associated to malignant TN. Conclusion Our data suggest a trend of over-diagnosing indolent thyroid cancer. The EU-TIRADS 4 score was not associated to TN malignancy. Considering clinical, accessory sonographic features and size threshold for FNAB in EU-TIRADS 4 score TN may refine the diagnosis performance of this score category in our population.
- 31 July 2024
- Published by University of Toronto Libraries - UOTL in University of Toronto Medical Journal
- Vol. 101 (2)
Open AccessPredicting malignancy of thyroid nodule using EU-TIRADS ultrasound score in an area of iodine deficiency
Background: In iodine-deficient region, thyroid nodules (TN) are more frequent and the proportion of benign nodules is higher compared to areas with sufficient iodine intake. Objective The aim of this study was to assess factors associated to malignant TN specially the Eu-TIRADS ultrasound score in a Moroccan population with high prevalence of iodine deficiency. Methods: In a prospective cross-sectional study, we enrolled outpatients referred for TN with Fine Needle Aspiration Biopsy (FNAB) indication according to EU-TIRADS 2017 classification. Malignancy of TN was defined by histological results indicating a thyroid malignancy on thyroid micro-biopsy or after surgical resection if indicated. Results: 225 TN were enrolled. The median of the patients’ age was 54 (42.5 ; 62) years-old. The prevalence of malignant TN was 8.9%. Malignant TN were significantly smaller than non-malignant ones (p = 0.008) and sub-centimetric TN were more frequent in malignant TN (25% vs 1.5%; p < 0.001). On multivariate analysis, male gender (OR : 9.33 ; 95% CI [2.02 ; 43.01]; p = 0,004) and EU-TIRADS 5 score (OR : 55.6 ; 95% CI [9.34 ; 327.91] ; p < 0.001) were independent factors associated with malignant TN. The EU-TIRADS 4 score was not associated to malignant TN. Conclusion Our data suggest a trend of over-diagnosing indolent thyroid cancer. The EU-TIRADS 4 score was not associated to TN malignancy. Considering clinical, accessory sonographic features and size threshold for FNAB in EU-TIRADS 4 score TN may refine the diagnosis performance of this score category in our population.
- 1 August 2023
- Published by JLE in Cahiers Santé Médecine thérapeutique
- Vol. 32 (4) , 192-195
Acute anterior uveitis under bisphosphonates: a serious complication to be aware of
- 1 August 2023
- Published by JLE in Cahiers Santé Médecine thérapeutique
- Vol. 32 (4) , 192-195
Acute anterior uveitis under bisphosphonates: a serious complication to be aware of
- Open Access
- 30 June 2023
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 12 (3) , 171-178
Management of Cardiovascular Risk among Moroccan Patients with Type 2 Diabetes: A Cross-Sectional Study
Objective: The aim of this study was to estimate the prevalence of cardiovascular disease and investigate cardiovascular risk management among type 2 diabetes (T2D) patients in the city of Meknes. Materials and methods: In a non-interventional cross-sectional study, we enrolled adult outpatients (≥ 18 years old) with T2D from the endocrinology and diabetology consultation of the Military Hospital of Meknes from June 2021 to January 2022. Informed consent was signed by all participants in the study. Assessment of cardiovascular risk was based on European Society of Cardiology (ESC) Guidelines on cardiovascular disease prevention in clinical practice of 2021. Clinical, biological and therapeutic data were compared between patients with and without cardiovascular disease. Data were analyzed using SPSS version 18 statistical software. Results: One hundred eighty T2D patients were enrolled. The mean age was 59.42 ± 8.72 years. The prevalence of cardiovascular disease was 13.3%. The prescription of statin (p < 0.001), antihypertensive treatment (p < 0.001) and platelet aggregation inhibitors (p < 0.001) was significantly higher in patients with cardiovascular disease. Overall, 5.6% patients were prescribed a blood glucose-lowering agent with demonstrated cardiovascular benefit. This prescription was higher in patients with cardiovascular disease (5 (20.8%) vs. 5 (3.2%); p = 0.004). It was found that 7.2% patients had an optimal cardiovascular risk factor management. Conclusions: The prevalence of cardiovascular disease among T2D patients is high in the city of Meknes. Despite an optimal prescription of cardiovascular medications, comprehensive control of cardiovascular risk factors is not achieved in most patients. The use of blood glucose-lowering agents with demonstrated cardiovascular benefit was low but significantly higher among patients with cardiovascular disease. Objective: The aim of this study was to estimate the prevalence of cardiovascular disease and investigate cardiovascular risk management among type 2 diabetes (T2D) patients in the city of Meknes. Materials and methods: In a non-interventional cross-sectional study, we enrolled adult outpatients (≥ 18 years old) with T2D from the endocrinology and diabetology consultation of the Military Hospital of Meknes from June 2021 to January 2022. Informed consent was signed by all participants in the study. Assessment of cardiovascular risk was based on European Society of Cardiology (ESC) Guidelines on cardiovascular disease prevention in clinical practice of 2021. Clinical, biological and therapeutic data were compared between patients with and without cardiovascular disease. Data were analyzed using SPSS version 18 statistical software. Results: One hundred eighty T2D patients were enrolled. The mean age was 59.42 ± 8.72 years. The prevalence of cardiovascular disease was 13.3%. The prescription of statin (p < 0.001), antihypertensive treatment (p < 0.001) and platelet aggregation inhibitors (p < 0.001) was significantly higher in patients with cardiovascular disease. Overall, 5.6% patients were prescribed a blood glucose-lowering agent with demonstrated cardiovascular benefit. This prescription was higher in patients with cardiovascular disease (5 (20.8%) vs. 5 (3.2%); p = 0.004). It was found that 7.2% patients had an optimal cardiovascular risk factor management. Conclusions: The prevalence of cardiovascular disease among T2D patients is high in the city of Meknes. Despite an optimal prescription of cardiovascular medications, comprehensive control of cardiovascular risk factors is not achieved in most patients. The use of blood glucose-lowering agents with demonstrated cardiovascular benefit was low but significantly higher among patients with cardiovascular disease.
- 30 June 2023
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 12 (3) , 171-178
Open AccessManagement of Cardiovascular Risk among Moroccan Patients with Type 2 Diabetes: A Cross-Sectional Study
Objective: The aim of this study was to estimate the prevalence of cardiovascular disease and investigate cardiovascular risk management among type 2 diabetes (T2D) patients in the city of Meknes. Materials and methods: In a non-interventional cross-sectional study, we enrolled adult outpatients (≥ 18 years old) with T2D from the endocrinology and diabetology consultation of the Military Hospital of Meknes from June 2021 to January 2022. Informed consent was signed by all participants in the study. Assessment of cardiovascular risk was based on European Society of Cardiology (ESC) Guidelines on cardiovascular disease prevention in clinical practice of 2021. Clinical, biological and therapeutic data were compared between patients with and without cardiovascular disease. Data were analyzed using SPSS version 18 statistical software. Results: One hundred eighty T2D patients were enrolled. The mean age was 59.42 ± 8.72 years. The prevalence of cardiovascular disease was 13.3%. The prescription of statin (p < 0.001), antihypertensive treatment (p < 0.001) and platelet aggregation inhibitors (p < 0.001) was significantly higher in patients with cardiovascular disease. Overall, 5.6% patients were prescribed a blood glucose-lowering agent with demonstrated cardiovascular benefit. This prescription was higher in patients with cardiovascular disease (5 (20.8%) vs. 5 (3.2%); p = 0.004). It was found that 7.2% patients had an optimal cardiovascular risk factor management. Conclusions: The prevalence of cardiovascular disease among T2D patients is high in the city of Meknes. Despite an optimal prescription of cardiovascular medications, comprehensive control of cardiovascular risk factors is not achieved in most patients. The use of blood glucose-lowering agents with demonstrated cardiovascular benefit was low but significantly higher among patients with cardiovascular disease. Objective: The aim of this study was to estimate the prevalence of cardiovascular disease and investigate cardiovascular risk management among type 2 diabetes (T2D) patients in the city of Meknes. Materials and methods: In a non-interventional cross-sectional study, we enrolled adult outpatients (≥ 18 years old) with T2D from the endocrinology and diabetology consultation of the Military Hospital of Meknes from June 2021 to January 2022. Informed consent was signed by all participants in the study. Assessment of cardiovascular risk was based on European Society of Cardiology (ESC) Guidelines on cardiovascular disease prevention in clinical practice of 2021. Clinical, biological and therapeutic data were compared between patients with and without cardiovascular disease. Data were analyzed using SPSS version 18 statistical software. Results: One hundred eighty T2D patients were enrolled. The mean age was 59.42 ± 8.72 years. The prevalence of cardiovascular disease was 13.3%. The prescription of statin (p < 0.001), antihypertensive treatment (p < 0.001) and platelet aggregation inhibitors (p < 0.001) was significantly higher in patients with cardiovascular disease. Overall, 5.6% patients were prescribed a blood glucose-lowering agent with demonstrated cardiovascular benefit. This prescription was higher in patients with cardiovascular disease (5 (20.8%) vs. 5 (3.2%); p = 0.004). It was found that 7.2% patients had an optimal cardiovascular risk factor management. Conclusions: The prevalence of cardiovascular disease among T2D patients is high in the city of Meknes. Despite an optimal prescription of cardiovascular medications, comprehensive control of cardiovascular risk factors is not achieved in most patients. The use of blood glucose-lowering agents with demonstrated cardiovascular benefit was low but significantly higher among patients with cardiovascular disease.
- 5 March 2021
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 10 (5) , 403-406
Autoantibodies in Moroccan patients with type 1 diabetes: Which one to choose?
Background. Immunological investigations are intend-ed for diagnosing T1D in atypical clinical presentation, also exploring the predisposition to T1D in a context of multiple autoimmune disorders or among the siblings of a patient with type 1 diabetes. While the diagnosing or the screening of T1D using five antibodies presents high expenses especially in emerging countries, it is for interest to determine their prevalence in order to choose the most frequent and most relevant. The aim of our study is to determine the prevalence of antibodies in Moroccan population. Methods. We investigated 62 T1D patients, the prevalence of autoantibodies was 74% for glutamic acid decarboxylase 65 autoantibody (GADA), 46% for insulinoma-associated protein 2 autoantibody (IA2A), and 3% for islet cell antibodies (ICA). GADA and/or IA2A were reported in all patients (100%). The GADA frequency was neither associated with the duration of diabetes nor the age of patients. Results. Finally, GADAs are by far the best markers for T1D, IA2As complements GADAs and increases the diagnostic sensitivity for detection of pancreatic autoimmunity and ICA should be abandoned because of its low prevalence. Background. Immunological investigations are intend-ed for diagnosing T1D in atypical clinical presentation, also exploring the predisposition to T1D in a context of multiple autoimmune disorders or among the siblings of a patient with type 1 diabetes. While the diagnosing or the screening of T1D using five antibodies presents high expenses especially in emerging countries, it is for interest to determine their prevalence in order to choose the most frequent and most relevant. The aim of our study is to determine the prevalence of antibodies in Moroccan population. Methods. We investigated 62 T1D patients, the prevalence of autoantibodies was 74% for glutamic acid decarboxylase 65 autoantibody (GADA), 46% for insulinoma-associated protein 2 autoantibody (IA2A), and 3% for islet cell antibodies (ICA). GADA and/or IA2A were reported in all patients (100%). The GADA frequency was neither associated with the duration of diabetes nor the age of patients. Results. Finally, GADAs are by far the best markers for T1D, IA2As complements GADAs and increases the diagnostic sensitivity for detection of pancreatic autoimmunity and ICA should be abandoned because of its low prevalence.
- 5 March 2021
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 10 (5) , 403-406
Autoantibodies in Moroccan patients with type 1 diabetes: Which one to choose?
Background. Immunological investigations are intend-ed for diagnosing T1D in atypical clinical presentation, also exploring the predisposition to T1D in a context of multiple autoimmune disorders or among the siblings of a patient with type 1 diabetes. While the diagnosing or the screening of T1D using five antibodies presents high expenses especially in emerging countries, it is for interest to determine their prevalence in order to choose the most frequent and most relevant. The aim of our study is to determine the prevalence of antibodies in Moroccan population. Methods. We investigated 62 T1D patients, the prevalence of autoantibodies was 74% for glutamic acid decarboxylase 65 autoantibody (GADA), 46% for insulinoma-associated protein 2 autoantibody (IA2A), and 3% for islet cell antibodies (ICA). GADA and/or IA2A were reported in all patients (100%). The GADA frequency was neither associated with the duration of diabetes nor the age of patients. Results. Finally, GADAs are by far the best markers for T1D, IA2As complements GADAs and increases the diagnostic sensitivity for detection of pancreatic autoimmunity and ICA should be abandoned because of its low prevalence. Background. Immunological investigations are intend-ed for diagnosing T1D in atypical clinical presentation, also exploring the predisposition to T1D in a context of multiple autoimmune disorders or among the siblings of a patient with type 1 diabetes. While the diagnosing or the screening of T1D using five antibodies presents high expenses especially in emerging countries, it is for interest to determine their prevalence in order to choose the most frequent and most relevant. The aim of our study is to determine the prevalence of antibodies in Moroccan population. Methods. We investigated 62 T1D patients, the prevalence of autoantibodies was 74% for glutamic acid decarboxylase 65 autoantibody (GADA), 46% for insulinoma-associated protein 2 autoantibody (IA2A), and 3% for islet cell antibodies (ICA). GADA and/or IA2A were reported in all patients (100%). The GADA frequency was neither associated with the duration of diabetes nor the age of patients. Results. Finally, GADAs are by far the best markers for T1D, IA2As complements GADAs and increases the diagnostic sensitivity for detection of pancreatic autoimmunity and ICA should be abandoned because of its low prevalence.